Abstract: The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.
Type:
Application
Filed:
December 19, 2023
Publication date:
April 25, 2024
Applicant:
The Children's Hospital of Philadelphia
Abstract: Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
Type:
Application
Filed:
October 30, 2023
Publication date:
March 28, 2024
Applicant:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
Type:
Application
Filed:
February 14, 2023
Publication date:
March 14, 2024
Applicants:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, The Children's Hospital of Philadelphia
Inventors:
Doris STOFFERS, Diva D. DE LEON, Charles STANLEY
Abstract: The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.
Type:
Application
Filed:
October 31, 2023
Publication date:
March 14, 2024
Applicants:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY
Inventors:
John M. MARIS, Kristopher R. BOSSE, Dimiter DIMITROV, Zhongyu ZHU, Dontcho V. JELEV
Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
Type:
Application
Filed:
October 30, 2023
Publication date:
March 7, 2024
Applicant:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Abstract: The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.
Abstract: Compositions for the identification of patients at risk for the development of latent autoimmune diabetes, and methods of use thereof, for the diagnosis and treatment of the same.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
February 6, 2024
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
Struan Frederick Grant, Rajashree Mishra
Abstract: A biometric sensor device system including a biometric sensor device, and a prediction computer. The biometric sensor device includes at least one camera, and a biometric sensor device processor configured to record a time synchronized communicative interaction between participants, by controlling at least one camera to record the participants over a time period, and transfer the recorded communicative interaction to the prediction computer. The prediction computer including a prediction computer processor configured to extract, from the recorded communicative interaction, a physical characteristic of each of the participants over the time period, compare the physical characteristic of at least one of the participants with the physical characteristic of at least another one of the participants over the time period, and classify or score at least one of the participants according to a predetermined classification or dimensional scoring scheme based on the comparison.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
January 30, 2024
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Robert Schultz, G. Keith Bartley, Evangelos Sariyanidi, Julia Parish-Morris
Abstract: Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
January 23, 2024
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
John Fraser Wright, Guang Qu, Bernd Hauck, Katherine A. High
Abstract: Provided herein are engineered red blood cells expressing rare blood antigen group profiles, and methods of making use the same, are described. Also provided are recombinant reagent red blood cells that express or lack the expression of at least one protein (e.g., a blood group antigen) on its surface and uses thereof.
Type:
Application
Filed:
June 6, 2023
Publication date:
January 18, 2024
Applicants:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA, NEW YORK BLOOD CENTER, INC.
Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.
Type:
Application
Filed:
April 27, 2023
Publication date:
December 28, 2023
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
Abstract: The invention relates to compositions and methods as part of a pharmacotherapeutic strategy that targets the endochondral ossification process in a pharmacologically selective and site-specific manner. A variety of orthopedic pathologies are caused by or associated with generalized or local dysregulation of endochondral ossification, for example trauma to the bone growth plate or diaphysis can cause a serious imbalance in bone growth, leading to progressive deformity that today can only be treated surgically. Dysregulated endochondral ossification is also behind heterotopic ossification, which arises in soft tissues and causes pain, decrease in mobility and other clinical problems. The invention therefore provides RARy agonist and antagonist nanoparticle compositions for treating abnormal endochondral ossification and bone growth that can deliver robust local therapeutic control over a particular long bone's growth with a long-lasting effect.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
December 5, 2023
Assignees:
University of Maryland, Baltimore, The Children's Hospital of Philadelphia
Abstract: The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.
Type:
Grant
Filed:
November 8, 2016
Date of Patent:
November 14, 2023
Assignees:
The Children's Hospital of Philadelphia, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
John M. Maris, Kristopher R. Bosse, Dimiter Dimitrov, Zhongyu Zhu, Dontcho V. Jelev
Abstract: Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
Abstract: In accordance with the present invention, a method for increasing the yield of rLV vector particles comprising a trans gene encoding a therapeutic protein or fragment thereof is disclosed. In one approach, cells are transfected with plasmids encoding the necessary components for rLV production using a calcium chloride transfection mix at pH 7.1 wherein the calcium chloride and plasmids form a complex which is added to the cells at a constant speed. The cells are then incubated for a suitable time period wherein virus particle media is collected at least twice during the incubation period and stored in a cold storage unit, thereby reducing virus inactivation.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
November 7, 2023
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Katherine A. High, John Fraser Wright, Bernd Hauck, Guang Qu
Abstract: Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Provided herein are viral vectors each comprising a modified capsid, wherein the modified capsid comprises at least one amino acid sequence that targets the viral vector to a distinct brain structure.
Type:
Application
Filed:
November 20, 2020
Publication date:
November 2, 2023
Applicant:
The Children's Hospital of Philadelphia
Inventors:
Beverly DAVIDSON, Yonghong CHEN, Paul T. RANUM, Xueyuan LIU